[{"address1": "5 Science Park", "address2": "395 Winchester Avenue", "city": "New Haven", "state": "CT", "zip": "06511", "country": "United States", "phone": "203 535 1456", "website": "https://www.arvinas.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.", "fullTimeEmployees": 445, "companyOfficers": [{"maxAge": 1, "name": "Dr. John G. Houston Ph.D.", "age": 63, "title": "Chairperson, CEO & President", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1144497, "exercisedValue": 0, "unexercisedValue": 12278804}, {"maxAge": 1, "name": "Dr. Ian  Taylor Ph.D.", "age": 61, "title": "President of Research & Development and Chairman of Scientific Advisory Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 732256, "exercisedValue": 0, "unexercisedValue": 1344633}, {"maxAge": 1, "name": "Mr. Andrew R. Saik", "age": 54, "title": "CFO & Treasurer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 24.92, "open": 25.01, "dayLow": 22.46, "dayHigh": 25.1, "regularMarketPreviousClose": 24.92, "regularMarketOpen": 25.01, "regularMarketDayLow": 22.46, "regularMarketDayHigh": 25.1, "beta": 1.967, "forwardPE": -4.820083, "volume": 655829, "regularMarketVolume": 655829, "averageVolume": 541528, "averageVolume10days": 628830, "averageDailyVolume10Day": 628830, "bid": 22.42, "ask": 22.58, "bidSize": 300, "askSize": 200, "marketCap": 1544670592, "fiftyTwoWeekLow": 20.28, "fiftyTwoWeekHigh": 53.08, "priceToSalesTrailing12Months": 9.588272, "fiftyDayAverage": 25.815, "twoHundredDayAverage": 31.99785, "currency": "USD", "enterpriseValue": 424570432, "profitMargins": -1.91558, "floatShares": 57184414, "sharesOutstanding": 68713104, "sharesShort": 8804546, "sharesShortPriorMonth": 10672118, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.12810001, "heldPercentInsiders": 0.07215, "heldPercentInstitutions": 1.08202, "shortRatio": 14.88, "shortPercentOfFloat": 0.1305, "impliedSharesOutstanding": 73309600, "bookValue": 8.53, "priceToBook": 2.6354046, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -308600000, "trailingEps": -4.79, "forwardEps": -4.66, "enterpriseToRevenue": 2.635, "enterpriseToEbitda": -1.204, "52WeekChange": 0.14469457, "SandP52WeekChange": 0.29098952, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARVN", "underlyingSymbol": "ARVN", "shortName": "Arvinas, Inc.", "longName": "Arvinas, Inc.", "firstTradeDateEpochUtc": 1538055000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5ab3d208-4f36-3880-916e-a34548e61b36", "messageBoardId": "finmb_243040896", "gmtOffSetMilliseconds": -18000000, "currentPrice": 22.48, "targetHighPrice": 110.0, "targetLowPrice": 28.0, "targetMeanPrice": 63.61111, "targetMedianPrice": 61.5, "recommendationKey": "none", "numberOfAnalystOpinions": 18, "totalCash": 1121600000, "totalCashPerShare": 16.323, "ebitda": -352600000, "totalDebt": 1500000, "quickRatio": 4.119, "currentRatio": 4.166, "totalRevenue": 161100000, "debtToEquity": 0.256, "revenuePerShare": 2.327, "returnOnAssets": -0.20069, "returnOnEquity": -0.59164, "freeCashflow": -170112496, "operatingCashflow": -258300000, "revenueGrowth": 1.96, "grossMargins": 1.0, "ebitdaMargins": -2.1887, "operatingMargins": -0.58887, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-16"}]